Avrupa Birliği - Romence - EMA (European Medicines Agency)

merck sharp dohme ltd - papilomavirus uman tip 6, proteina l1, papilomavirus uman tip 11 proteina l1, papilomavirus uman de tip 16 proteina l1, papilomavirus uman tip 18 proteina l1 - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vaccinuri - silgard este un vaccin utilizat la vârsta de 9 ani pentru prevenirea:leziuni genitale precanceroase (cervicale, vulvare și vaginale), premaligne leziunilor anale, cancer de col uterin și cancer anal cauzal legate de anumite oncogene de papilomavirus uman (hpv), tipurile;veruci genitale (condyloma acuminata) cauzal legate de anumite tipuri de hpv. vezi secțiunile 4. 4 și 5. 1 pentru informații importante privind datele care susțin această indicație. utilizarea de silgard ar trebui să fie în conformitate cu recomandările oficiale.

Avrupa Birliği - Romence - EMA (European Medicines Agency)

dompe farmaceutici s.p.a. - recombinant human nerve growth factor - cheratită - oftalmologice - tratamentul defectelor moderate (defecte epiteliale persistente) sau severe (ulcer corneei) keratitei neurotrofice la adulți.

Avrupa Birliği - Romence - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - policitemia vera - imunostimulante, - besremi este indicat ca monoterapie la adulți pentru tratamentul policitemiei vera, fără simptomatic splenomegalie.

Avrupa Birliği - Romence - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab brentuximab - limfom cu celule b - agenți antineoplazici - polivy în combinație cu bendamustina și rituximab este indicat pentru tratamentul pacienților adulți cu recăderi/refractară diffuse large b-cell lymphoma (dlbcl) care nu sunt candidați pentru transplant de celule stem hematopoietice. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Avrupa Birliği - Romence - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunosupresoare - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Avrupa Birliği - Romence - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccinuri - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Avrupa Birliği - Romence - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leucemia, celulă păr - agenți antineoplazici - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Avrupa Birliği - Romence - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porci - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Avrupa Birliği - Romence - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccinuri - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Avrupa Birliği - Romence - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - pui - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.